Positron emission tomography in mantle cell lymphoma

Leukemia and Lymphoma

Volumn 49, Issue 9, 2008, Pages 1693-1701

  Brepoels, Lieselot ^a   Stroobants, Sigrid ^a   De Wever, Walter ^a   Dierickx, Daan ^a   Vandenberghe, Peter ^a   Thomas, Jose ^a   Mortelmans, Luc ^a   Verhoef, Gregor ^a   De Wolf Peeters, Christiane ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Chemotherapeutic approaches; Drug resistance; FDG; Lymphoma and Hodgkin disease; Mantle cell lymphoma; Neoplasia; PET; Response assessment

Indexed keywords

CISPLATIN; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; RITUXIMAB;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 52349111561     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802216707     Document Type: Article

References (24)

1. Lenz, G., Dreyling, M. and Hiddemann, W. (2004) Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol, 83, pp. 71-77.
2. Weigert, O., Unterhalt, M., Hiddemann, W. and Dreyling, M. (2007) Current management of mantle cell lymphoma. Drugs, 67, pp. 1689-1702.
3. Jacobsen, E. and Freedman, A. (2004) An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma. Curr Opin Oncol, 16, pp. 106-113.
4. Tiemann, M., Schrader, C., Klapper, W., Dreyling, M. H., Campo, E. Norton, A. et al. (2005) Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): A clinicopathological study from the European MCL Network. Br J Haematol, 131, pp. 29-38.
5. Bosch, F., Lopez-Guillermo, A., Campo, E., Ribera, J. M., Conde, E. Piris, M. A. et al. (1997) Mantle cell lymphoma. Presenting features, response to therapy, and prognostic factors. Cancer, 82, pp. 567-575.
6. Argatoff, L. H., Connors, J. M., Klasa, R. J., Horsman, D. E. and Gascoyne, R. D. (1997) Mantle cell lymphoma: A clinicopathologic study of 80 cases. Blood, 89, pp. 2067-2078.
7. Bernard, M., Gressin, R., Lefrere, F., Drenou, B., Branger, B. Caulet-Maugendre, S. et al. (2001) Blastic variant of mantle cell lymphoma: A rare but highly aggressive subtype. Leukemia, 15, pp. 1785-1791.
8. Brepoels, L., Stroobants, S., de Wever, W., Spaepen, K., Vandenberghe, P. Thomas, J. et al. (2007) Hodgkin lymphoma: Response assessment by Revised International Workshop Criteria. Leuk Lymphoma, 48, pp. 1539-1547.
9. Brepoels, L., Stroobants, S., De Wever, W., Spaepen, K., Vandenberghe, P. Thomas, J. et al. (2007) Aggressive and indolent non-Hodgkin's lymphoma: Response assessment by Integrated International Workshop Criteria. Leuk Lymphoma, 48, pp. 1522-1530.
10. Tsukamoto, N., Kojima, M., Hasegawa, M., Oriuchi, N., Matsushima, T. Yokohama, A. et al. (2007) The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: Relation to histologic subtypes based on the World Health Organization classification. Cancer, 110, pp. 652-659.
11. Elstrom, R., Guan, L., Baker, G., Nakhoda, K., Vergilio, J. A. Zhuang, H. et al. (2003) Utility of FDG-PET scanning in lymphoma by WHO classification. Blood, 101, pp. 3875-3876.
12. Karam, M., Matthew, J., Shet, N. and Ashar, Ata (2007) FDG-PET study may identify mantle cell lymphoma patients with an unusually favourable prognosis. J Nucl Med, 48, p. 148P.
13. Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink, H. K. Vardiman, J. et al. (2000) The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology, 36, pp. 69-86.
14. Dreger, P., Martin, S., Kuse, R., Sonnen, R., Glass, B. Kroger, N. et al. (2000) The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: A joint analysis of two prospective studies with 46 patients. Hematol J, 1, pp. 87-94.
15. De Wever, W., Vankan, Y., Stroobants, S. and Verschakelen, J. (2007) Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer. Eur Respir J, 29, pp. 995-1002.
16. Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L. Horning, S. J. et al. (2007) Revised response criteria for malignant lymphoma. J Clin Oncol, 1025, pp. 579-586.
17. Young, H., Baum, R., Cremerius, U., Herholz, K., Hoekstra, O. Lammertsma, A. A. et al. (1999) Measurement of clinical and subclinical tumour response using 18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. Eur J Cancer, 35, pp. 1773-1782.
18. Juweid, M. E., Stroobants, S., Hoekstra, O. S., Mottaghy, F. M., Dietlein, M. Guermazi, A. et al. (2007) Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol, 25, pp. 571-578.
19. Kaplan, E. S. and Meier, P. (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc, 58, pp. 457-481.
20. Pott, C., Schrader, C., Bruggemann, M., Ritgen, M., Harder, L. Raff, T. et al. (2005) Blastoid variant of mantle cell lymphoma: Late progression from classical mantle cell lymphoma and quantitation of minimal residual disease. Eur J Haematol, 74, pp. 353-358.
21. Bruzzi, J. F., Macapinlac, H., Tsimberidou, A. M., Truong, M. T., Keating, M. J., Marom, E. M. and Munden, R. F. (2006) Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med, 7, pp. 1267-1273.
22. Howard, O. M., Gribben, J. G., Neuberg, D. S., Grossbard, M., Poor, C., Janicek, M. J. and Shipp, M. A. (2002) Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival. J Clin Oncol, 20, pp. 1288-1294.
23. de Geus-Oei, L. F., van der Heijden, H. F., Corstens, F. H. and Oyen, W. J. (2008) Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: A systematic review. Cancer, 110, pp. 1654-1664.
24. Jerusalem, G., Beguin, Y., Fassotte, M. F., Belhocine, T., Hustinx, R., Rigo, P. and Fillet, G. (2003) Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol, 14, pp. 123-130.